Remove 2024 Remove Ablation Remove Circulation
article thumbnail

Boston Scientific Initiates AVANT GUARD Clinical Trial to Evaluate FARAPULSE Pulsed Field Ablation System as First-Line Treatment for Persistent Atrial Fibrillation

DAIC

Outcomes of ablation with the FARAPULSE PFA System – a nonthermal treatment in which electric fields selectively ablate heart tissue – will be compared to outcomes following use of anti-arrhythmic drug (AAD) therapy, which is commonly prescribed for patients living with persistent AF. Circulation. Not available for sale.

article thumbnail

Biosense Webster Study Supports Low and Zero Fluoroscopy Workflow as Safe, Effective Alternative to Conventional Catheter Ablation

DAIC

milla1cf Fri, 02/02/2024 - 17:02 February 2, 2024 — Biosense Webster, Inc. , Titled "Real-world Data Affirms Safety and Effectiveness of Low/Zero Fluoroscopy Atrial Fibrillation Ablation," the study was presented as a late-breaker at the 29th Annual International AF Symposium.

Ablation 105
article thumbnail

Medtronic Creates History with FDA Approval of its Novel PulseSelect Pulsed Field Ablation System to Treat Atrial Fibrillation

DAIC

Launching the first FDA -approved PFA technology is not just a milestone; the PulseSelect PFA system is setting a new standard in safety for AF ablation with excellent efficacy and efficiency 1. In my clinical experience with the catheter, it was designed for AF ablation procedures.

article thumbnail

Patients With Advanced Heart Failure and Atrial Fibrillation Deserve an Attempt at Catheter Ablation as First-Line Therapy

Circulation

Circulation, Volume 150, Issue 16 , Page 1220-1222, October 15, 2024.

article thumbnail

Biosense Webster Submits Application to U.S. FDA Seeking Approval of the VARIPULSE Platform for the Treatment of Paroxysmal Atrial Fibrillation

DAIC

milla1cf Thu, 03/28/2024 - 07:28 March 28, 2024 — Biosense Webster, Inc., patients, were presented as a late-breaker at the 2024 AF Symposium. 1 Among 20 patients who completed the 12-month follow-up visit, 100% achieved acute success from ablation procedures and 80% remained free from atrial arrhythmia recurrence at one year.

article thumbnail

Biosense Webster Announces CE Mark approval in Europe for VARIPULSE Pulsed Field Ablation (PFA) Platform

DAIC

milla1cf Tue, 03/05/2024 - 12:02 March 5, 2024 — Biosense Webster, Inc. , Most importantly, the recent published data on the VARIPULSE Platform demonstrates the safety using pulsed field ablation for patients being treated for AF." iii] The study reported a low fluoroscopy time of 7.8

article thumbnail

Ablation of Cardiac Arrhythmias: Past, Present, and Future

Circulation

Circulation, Volume 150, Issue 1 , Page 4-6, July 2, 2024.